New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Tvardi Therapeutics, Inc.

TVRD

Healthcare Biotechnology

Tvardi Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $7.1 million, down 66.0% from fiscal 2023.

Revenue
+20.3%
EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

0.99 0.04 +4.21%

After hours trading: 0.97, down 2.02%, last trade Fri 7:28pm Eastern.

Market cap
$12.6M
P/E
n/m
Fwd P/E FY25e
n/m
Dividend yield
—
F-score
3/9
ROIC
0.00%
Net debt / EBITDA
1.1×
Payout ratio
—

Revenue to profit Fiscal 2024, year to Dec 31, 2024

It lost $29.4M on $7.1M of revenue: $411.90 for every $100. What is an income statement?

Revenue to profit, in millions of dollars and as a share of revenue
Revenue7.1100.0%
Cost of revenue−0.6−8.7%
Gross profit6.591.3%
Research & development−23.7−331.4%
Selling, general & admin−4.5−62.4%
Other operating costs−6.5−91.3%
Operating income−28.1−393.8%
Other income, net−1.3−18.1%
Income tax+0.45.6%
Other items−0.4−5.6%
Net income−29.4−411.9%
RevenueOperating incomeNet incomeNet margin (right axis)
Revenue, operating income and net income, nine years
FY16FY17FY18FY19FY20FY21FY22FY23FY24
Revenue$0.0B$0.9M$13M$20M$135M$23M$42M$21M$7.1M
Operating income−$58M−$59M−$77M−$112M$5.4M−$89M−$88M−$121M−$28M
Net income−$57M−$58M−$74M−$106M$8.4M−$88M−$85M−$119M−$29M
Net margin (right axis)−66604.7%−6380.4%−549.5%−534.9%6.2%−384.1%−204.2%−565.2%−411.9%
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Revenue
— 7.14 20.97 41.87 23.03 135.08 19.89 13.47 0.91 0.09
Revenue Growth
— (65.96%) (49.92%) 81.81% (82.95%) 579.28% 47.64% 1,378.49% 959.30% (97.74%)
Gross Profit
— 6.52 14.79 34.60 23.03 135.08 19.89 13.47 0.91 0.09
Operating Income
(26.75) (28.11) (121.49) (87.53) (89.08) 5.39 (111.68) (77.38) (59.48) (58.40)
EBT
(18.21) (29.40) (118.51) (85.47) (88.44) 7.72 (107.19) (74.40) (58.33) (57.75)
Income after Tax
(18.21) (29.40) (118.51) (85.47) (88.44) 8.41 (106.37) (74.01) (58.12) (57.28)
Net Income Common
(18.21) (29.40) (118.51) (85.47) (88.44) 8.41 (106.37) (74.01) (58.12) (57.28)
EPS (Diluted)
(3.26) (11.42) (78.88) (57.27) (62.67) 6.48 (89.68) (74.20) (66.99) (75.64)
Shares (Diluted, Weighted)
7.78 2.57 1.50 1.49 1.41 1.33 1.18 1.00 0.87 0.76
Gross Margin
— 91.31% 70.56% 82.65% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBIT Margin
— (393.82%) (579.43%) (209.08%) (386.85%) 3.99% (561.60%) (574.52%) (6,529.64%) (67,906.98%)
Net Profit Margin
— (411.90%) (565.21%) (204.16%) (384.06%) 6.23% (534.91%) (549.51%) (6,380.35%) (66,604.65%)
Free Cash Flow Margin
— (271.14%) (450.46%) (188.15%) (260.80%) (4.32%) (549.35%) (166.11%) (6,020.20%) (55,927.91%)
EBITDA
(26.85) (28.01) (119.56) (85.60) (86.67) 6.55 (112.26) (78.83) (59.57) (57.15)
EBIT
(26.75) (28.11) (121.49) (87.53) (89.08) 5.39 (111.68) (77.38) (59.48) (58.40)

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 17, 2026